Thomas Hügle

University Hospital Lausanne (CHUV)
Lausann, Switzerland

AbbVie (Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Eli Lilly (Consultant/Advisory Board)Janssen (Consultant/Advisory Board, Speaker/Honoraria includes speakers bureau, symposia, and expert witness)Menarini (Speaker/Honoraria includes speakers bureau, symposia, and expert witness)Novartis (Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Pfizer (Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)

Presentation(s):

• Patient Groups in Rheumatoid Arthritis Identified by Deep Learning Respond Differently to Biologic or Targeted Synthetic Disease Modifying Antirheumatic Drugs

  Friday, August 26, 2022
  6:00 PM – 6:15 PM CEST